Literature DB >> 32453077

FDG PET/CT in a Patient With Mantle Cell Lymphoma and COVID-19: Typical Findings.

Margot Playe1, Justine Siavellis2, Thorsten Braun2, Michaël Soussan.   

Abstract

A 52-year-old woman with no medical history was admitted on March 18, 2020, presenting since 3 days asthenia, abdominal pain, and dry cough but no fever. Adenomegalies, splenomegaly, leukocytosis, and elevated LDH suggested mature lymphoproliferation. Considering the current health context, an RT-PCR testing for COVID-19 (coronavirus disease 2019) was performed and found to be positive. Early chest CT showed no sign of pulmonary infection but multiple adenomegalies. An F-FDG PET/CT performed 5 days later to assess the extent of the hemopathy revealed the apparition of FDG-avid bilateral ground glass and subpleural curvilinear opacities suggesting COVID-19-associated pneumopathy.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32453077      PMCID: PMC7268867          DOI: 10.1097/RLU.0000000000003113

Source DB:  PubMed          Journal:  Clin Nucl Med        ISSN: 0363-9762            Impact factor:   10.782


The association of clinical splenomegaly, axillary, and inguinal lymphadenopathies with high blood lactate dehydrogenase level and leukocytosis suggested mature lymphoproliferation. An 18F-FDG PET/CT scan was performed. A, FDG PET MIP image. B, PET/CT fusion. C, Postcontrast chest CT axial slices. Thoracic and subdiaphragmatic lymph node involvement with high FDG uptake (SUVmax, 8.7; arrows). Note a major mesenteric infiltration (arrowheads). Inguinal lymph node biopsy specimen confirmed mantle cell lymphoma with high proliferative index (Ki67 = 70%). FDG PET/CT (A) and chest CT (B) axial slices: bilateral ground glass opacities (arrows) and curvilinear opacities (arrowheads), with predominance in the posterior subpleural areas, suggesting installation of COVID-19–associated pneumopathy. These findings were associated with a moderate FDG uptake (SUVmax, 4). This case illustrates the typical chest CT findings in COVID-19 recently described: possible negativity within the first 3 days of clinical onset in 50% of cases[1]; multiple bilateral ground glass opacities, curvilinear subpleural opacities, and predominance in middle and lower lobes and posterior areas, septal thickening, and crazy paving pattern[2-4]; and progressive transformation into multifocal consolidative opacities, with greatest severity about 10 days after the clinical onset.[5] A study including 1014 cases in Wuhan (China) demonstrated the high sensitivity (97%) of chest CT for diagnosis of COVID-19.[6] Radiologic evaluation of disease extent has also a probable prognostic implication.[7] A lobar alveolar consolidation with adenomegalies should raise the diagnosis of bacterial coinfection. This case highlights the PET/CT features of COVID-19, in accordance with recent publications[8,9]: FDG moderate to intense uptake, as commonly seen in pulmonary infections. Considering the heterogeneous clinical setup of the disease, the rapid increase in the number of cases worldwide, the rate of false-negative of RT-PCR (approximately 33%),[6] and, finally, our patients’ profile with severe comorbidities and potential immunosuppressive therapies, nuclear medicine specialists should carefully describe and report these patterns.
  8 in total

1.  Relation Between Chest CT Findings and Clinical Conditions of Coronavirus Disease (COVID-19) Pneumonia: A Multicenter Study.

Authors:  Wei Zhao; Zheng Zhong; Xingzhi Xie; Qizhi Yu; Jun Liu
Journal:  AJR Am J Roentgenol       Date:  2020-03-03       Impact factor: 3.959

2.  Coronavirus Disease 2019 (COVID-19): A Systematic Review of Imaging Findings in 919 Patients.

Authors:  Sana Salehi; Aidin Abedi; Sudheer Balakrishnan; Ali Gholamrezanezhad
Journal:  AJR Am J Roentgenol       Date:  2020-03-14       Impact factor: 3.959

3.  Chest CT Findings in Coronavirus Disease-19 (COVID-19): Relationship to Duration of Infection.

Authors:  Adam Bernheim; Xueyan Mei; Mingqian Huang; Yang Yang; Zahi A Fayad; Ning Zhang; Kaiyue Diao; Bin Lin; Xiqi Zhu; Kunwei Li; Shaolin Li; Hong Shan; Adam Jacobi; Michael Chung
Journal:  Radiology       Date:  2020-02-20       Impact factor: 11.105

4.  Correlation of Chest CT and RT-PCR Testing for Coronavirus Disease 2019 (COVID-19) in China: A Report of 1014 Cases.

Authors:  Tao Ai; Zhenlu Yang; Hongyan Hou; Chenao Zhan; Chong Chen; Wenzhi Lv; Qian Tao; Ziyong Sun; Liming Xia
Journal:  Radiology       Date:  2020-02-26       Impact factor: 11.105

5.  Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study.

Authors:  Heshui Shi; Xiaoyu Han; Nanchuan Jiang; Yukun Cao; Osamah Alwalid; Jin Gu; Yanqing Fan; Chuansheng Zheng
Journal:  Lancet Infect Dis       Date:  2020-02-24       Impact factor: 25.071

6.  Performance of Radiologists in Differentiating COVID-19 from Non-COVID-19 Viral Pneumonia at Chest CT.

Authors:  Harrison X Bai; Ben Hsieh; Zeng Xiong; Kasey Halsey; Ji Whae Choi; Thi My Linh Tran; Ian Pan; Lin-Bo Shi; Dong-Cui Wang; Ji Mei; Xiao-Long Jiang; Qiu-Hua Zeng; Thomas K Egglin; Ping-Feng Hu; Saurabh Agarwal; Fang-Fang Xie; Sha Li; Terrance Healey; Michael K Atalay; Wei-Hua Liao
Journal:  Radiology       Date:  2020-03-10       Impact factor: 11.105

7.  FDG PET/CT of COVID-19.

Authors:  Sijuan Zou; Xiaohua Zhu
Journal:  Radiology       Date:  2020-03-06       Impact factor: 11.105

8.  18F-FDG PET/CT findings of COVID-19: a series of four highly suspected cases.

Authors:  Chunxia Qin; Fang Liu; Tzu-Chen Yen; Xiaoli Lan
Journal:  Eur J Nucl Med Mol Imaging       Date:  2020-02-22       Impact factor: 9.236

  8 in total
  2 in total

1.  FDG PET/CT findings and post-treatment changes of COVID-19 pneumonia in a patient with lymphoma: A case report.

Authors:  Joy Matsui; Asha Kandathil; Fangyu Peng
Journal:  Mol Clin Oncol       Date:  2021-12-31

2.  99mTc-Leukocyte Scintigraphy Revealed Viral Pulmonary Infection in a COVID-19 Patient.

Authors:  Jiefu Zheng; Yiyan Liu
Journal:  Clin Nucl Med       Date:  2020-10       Impact factor: 10.782

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.